/DISREGARD RELEASE: Celltrion/
News Provided by PR Newswire2025-05-23
33 Views
/DISREGARD RELEASE: Celltrion/ |
| [23-May-2025] |
We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire. SOURCE Celltrion | ||
Company Codes: Korea:068270 |
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
BREAKING NEWS: Herbal Works Inc. Announces That It Has Retained Greta Gaines to Develop High End Luxury Beauty Products
